Clinical Trial Update: Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates the CXCR4 antagonist BMS-936564 alone and in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone for relapsed/r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BMS-936564
• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED